ReviewLife (Basel, Switzerland)2023
Evolving Diagnostic and Management Advances in Coronary Heart Disease.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Hand Dysfunction After Intervention via Distal Versus Conventional Transradial Access: A Meta-Analysis of Randomized Trials.Clinical cardiology · 2026Pooled it
- Effects of the pre-existing coronary heart disease on the prognosis of COVID-19 patients: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Impact of peripheral arterial disease and cerebrovascular disease on outcomes in patients undergoing PCI.International journal of cardiology. Heart & vasculature · 2026Article
- Extension of Atherosclerosis ApoE-/- Mouse-a Model of Chronic Myocardial Ischemia and Evaluation Method.Journal of cardiovascular translational research · 2026Article
- Machine learning and Mendelian randomization identify key lifestyle factors in coronary heart disease: A NHANES-Based study.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Expression level and clinical significance of IL-29 in serum of patients with coronary heart disease.Journal of cardiothoracic surgery · 2025Article
- Linking sequence restoration capability of shuffled coronary angiography to coronary artery disease diagnosis.Scientific reports · 2025Article
- CircBTBD7-420aa Encoded by hsa_circ_0000563 Regulates the Progression of Atherosclerosis and Construction of circBTBD7-420aa Engineered Exosomes.JACC. Basic to translational science · 2025Article
- The pathophysiological mechanisms of immunosenescence in coronary artery disease.Frontiers in cell and developmental biology · 2025Review
- Shared Genetic Characteristics of Coronary Artery Disease and Peripheral artery Disease: Insights From Integrated Bioinformatics Analysis of RNA-Sequencing Data.Bioinformatics and biology insights · 2025Article
- Disparities in chronic ischemic heart disease-related mortality across sex, race, and urbanization status in the United States, 1999-2019.PLOS global public health · 2025Article
- The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs.Advances in therapy · 2024Article
- Intramyocardial Injection of Hypoxia-Conditioned Extracellular Vesicles Modulates Response to Oxidative Stress in the Chronically Ischemic Myocardium.Bioengineering (Basel, Switzerland) · 2024Article
- Influence of Previous Coronary Artery Bypass Grafting on Clinical Outcomes After Percutaneous Coronary Intervention: A Meta-Analysis of 250 684 Patients.Clinical Medicine Insights. Cardiology · 2024Article
- Review
- Advancing cardiovascular imaging in Iraq: infrastructure, gender diversity, and future perspectives.Therapeutic advances in cardiovascular diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite considerable improvement in diagnostic modalities and therapeutic options over the last few decades, the global burden of ischemic heart disease is steadily rising, remaining a major cause of death worldwide. Thus, new strategies are needed to lessen cardiovascular events. Researchers in different areas such as biotechnology and tissue engineering have developed novel therapeutic strategies such as stem cells, nanotechnology, and robotic surgery, among others (3D printing and drugs). In addition, advances in bioengineering have led to the emergence of new diagnostic and prognostic techniques, such as quantitative flow ratio (QFR), and biomarkers for atherosclerosis. In this review, we explore novel diagnostic invasive and noninvasive modalities that allow a more detailed characterization of coronary disease. We delve into new technological revascularization procedures and pharmacological agents that target several residual cardiovascular risks, including inflammatory, thrombotic, and metabolic pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.